Enzo Biochem Valuation
Is EZB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of EZB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: EZB (€0.92) is trading below our estimate of fair value (€11.45)
Significantly Below Fair Value: EZB is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EZB?
Key metric: As EZB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is EZB's PS Ratio? | |
|---|---|
| PS Ratio | 1.6x |
| Sales | US$31.91m |
| Market Cap | US$50.68m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.06x |
| Enterprise Value/EBITDA | -0.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does EZB's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.6x | ||
V3V VITA 34 | 0.9x | 3.1% | €72.5m |
SYAB SYNLAB | 1x | 4.4% | €2.5b |
HAEK HAEMATO | 0.3x | n/a | €68.0m |
MAK Maternus-Kliniken | 0.3x | n/a | €33.6m |
EZB Enzo Biochem | 1.6x | n/a | €50.7m |
Price-To-Sales vs Peers: EZB is expensive based on its Price-To-Sales Ratio (1.6x) compared to the peer average (0.6x).
Price to Sales Ratio vs Industry
How does EZB's PS Ratio compare vs other companies in the DE Healthcare Industry?
| 1 Company | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
TLIK Arzneiwerk VIDA | 0.08x | n/a | US$4.67m |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: EZB is expensive based on its Price-To-Sales Ratio (1.6x) compared to the European Healthcare industry average (0.6x).
Price to Sales Ratio vs Fair Ratio
What is EZB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.6x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate EZB's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Fagron
€1.3b
A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
4A5
€18.18
7D
-2.7%
1Y
6.1%
Shandong Weigao Group Medical Polymer
HK$20.7b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.54
7D
-1.8%
1Y
-37.1%
LNA Santé
€242.3m
Engages in the management and operation of health establishments.
2N3
€23.25
7D
-6.8%
1Y
15.7%